BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32953984)

  • 1. CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease.
    Slabik C; Kalbarczyk M; Danisch S; Zeidler R; Klawonn F; Volk V; Krönke N; Feuerhake F; Ferreira de Figueiredo C; Blasczyk R; Olbrich H; Theobald SJ; Schneider A; Ganser A; von Kaisenberg C; Lienenklaus S; Bleich A; Hammerschmidt W; Stripecke R
    Mol Ther Oncolytics; 2020 Sep; 18():504-524. PubMed ID: 32953984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies.
    Zhang X; Wang T; Zhu X; Lu Y; Li M; Huang Z; Han D; Zhang L; Wu Y; Li L; Klawonn F; Stripecke R
    Front Immunol; 2023; 14():1103695. PubMed ID: 36817460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-viral
    Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
    Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 Blockade Aggravates Epstein-Barr Virus
    Volk V; Theobald SJ; Danisch S; Khailaie S; Kalbarczyk M; Schneider A; Bialek-Waldmann J; Krönke N; Deng Y; Eiz-Vesper B; Dragon AC; von Kaisenberg C; Lienenklaus S; Bleich A; Keck J; Meyer-Hermann M; Klawonn F; Hammerschmidt W; Delecluse HJ; Münz C; Feuerhake F; Stripecke R
    Front Oncol; 2020; 10():614876. PubMed ID: 33511078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
    Herrman M; Mühe J; Quink C; Wang F
    J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture.
    Tanner JE; Hu J; Alfieri C
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29642526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation.
    Dragon AC; Zimmermann K; Nerreter T; Sandfort D; Lahrberg J; Klöß S; Kloth C; Mangare C; Bonifacius A; Tischer-Zimmermann S; Blasczyk R; Maecker-Kolhoff B; Uchanska-Ziegler B; Abken H; Schambach A; Hudecek M; Eiz-Vesper B
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33127653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and characterization of Epstein-Barr virus gp350-expressing transfected human lymphoid (Raji) cell clones.
    Khyatti M; Patel PC; Menezes J
    Int J Cancer; 1991 Jun; 48(4):591-7. PubMed ID: 1646179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
    Khyatti M; Patel PC; Stefanescu I; Menezes J
    J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections.
    Olbrich H; Theobald SJ; Slabik C; Gerasch L; Schneider A; Mach M; Shum T; Mamonkin M; Stripecke R
    Hum Gene Ther; 2020 Apr; 31(7-8):423-439. PubMed ID: 32159399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.
    Ma SD; Xu X; Jones R; Delecluse HJ; Zumwalde NA; Sharma A; Gumperz JE; Kenney SC
    PLoS Pathog; 2016 May; 12(5):e1005642. PubMed ID: 27186886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.
    Sashihara J; Hoshino Y; Bowman JJ; Krogmann T; Burbelo PD; Coffield VM; Kamrud K; Cohen JI
    PLoS Pathog; 2011 Oct; 7(10):e1002308. PubMed ID: 22028652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
    Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
    J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
    Church TM; Verma D; Thompson J; Swaminathan S
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.